2. Search Result
Search Result
Results for "

L-2-Aminobutyric acid

" in MedChemExpress (MCE) Product Catalog:

8

Inhibitors & Agonists

3

Peptides

2

Natural
Products

3

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-W010589
    L-2-Aminobutyric acid

    H-Abu-OH

    		 Endogenous Metabolite Drug Intermediate Metabolic Disease
    L-2-Aminobutyric acid (H-Abu-OH) is a non-proteinogenic amino acid that exists in human tissues and body fluids. L-2-Aminobutyric acid is formed by the transamination of oxobutyric acid. L-2-Aminobutyric acid can serve as a precursor for anticonvulsant and anti-tuberculosis agents and is a key intermediate in the chemical and pharmaceutical industries.
    L-2-Aminobutyric acid
  • HY-P10341
    ZP3022

    		GCGR Metabolic Disease
    ZP3022 is a dual agonist of glucagon-like peptide-1 (GLP-1) and gastrin that has the ability to sustainably improve glycemic control. Additionally, ZP3022 can effectively increase β-cell mass, promote β-cell proliferation, and enhance the function of pancreatic islets. ZP3022 can be used in anti-diabetic research .
    ZP3022
  • HY-W010589R
    L-2-Aminobutyric acid (Standard)

    H-Abu-OH (Standard)

    		 Reference Standards Endogenous Metabolite Drug Intermediate Metabolic Disease
    L-2-Aminobutyric acid (Standard) is the analytical standard of L-2-Aminobutyric acid. This product is intended for research and analytical applications. L-2-Aminobutyric acid is a non-proteinogenic amino acid that exists in human tissues and body fluids. L-2-Aminobutyric acid is formed by the transamination of oxobutyric acid. L-2-Aminobutyric acid can serve as a precursor for anticonvulsant and anti-tuberculosis agents and is a key intermediate in the chemical and pharmaceutical industries.
    L-2-Aminobutyric acid (Standard)
  • HY-W710927
    L-2-Aminobutyric acid-d5

    		Isotope-Labeled Compounds Endogenous Metabolite Metabolic Disease
    L-2-Aminobutyric acid-d5 is the deuterium labeled H-Abu-OH (HY-W010589). H-Abu-OH, one of the three isomers of aminobutyric acid, is elevated in the plasma of children with with Reye's syndrome, tyrosinemia, homocystinuria, nonketotic hyperglycinemia, and ornithine transcarbamylase deficiency.
    L-2-Aminobutyric acid-d5
  • HY-W010589S2
    L-2-Aminobutyric acid-d6

    H-Abu-OH-d6

    		 Isotope-Labeled Compounds Endogenous Metabolite Drug Intermediate Metabolic Disease
    L-2-Aminobutyric acid-d6 is the deuterium labeled L-2-Aminobutyric acid. L-2-Aminobutyric acid is a non-proteinogenic amino acid that exists in human tissues and body fluids. L-2-Aminobutyric acid is formed by the transamination of oxobutyric acid. L-2-Aminobutyric acid can serve as a precursor for anticonvulsant and anti-tuberculosis agents and is a key intermediate in the chemical and pharmaceutical industries.
    L-2-Aminobutyric acid-d6
  • HY-W010589S
    L-2-Aminobutyric acid-d3

    H-Abu-OH-d3

    		 Isotope-Labeled Compounds Endogenous Metabolite Drug Intermediate Metabolic Disease
    L-2-Aminobutyric acid-d3 is the deuterium labeled L-2-Aminobutyric acid. L-2-Aminobutyric acid is a non-proteinogenic amino acid that exists in human tissues and body fluids. L-2-Aminobutyric acid is formed by the transamination of oxobutyric acid. L-2-Aminobutyric acid can serve as a precursor for anticonvulsant and anti-tuberculosis agents and is a key intermediate in the chemical and pharmaceutical industries.
    L-2-Aminobutyric acid-d3
  • HY-P11243
    EphA4 agonist compound 23

    		Ephrin Receptor Neurological Disease
    EphA4 agonist compound 23 is a novel EphA4 agonist peptide mimic. EphA4 agonist compound 23 exhibits high affinity, high selectivity, and significant receptor activation ability. EphA4 agonist compound 23 is commonly used in the study of neurodegenerative diseases .
    EphA4 agonist compound 23
  • HY-P10876
    mcK6A1

    		Amyloid-β Neurological Disease
    mcK6A1 is an inhibitor for the aggregation of amyloid-β (Aβ), that selectively binds to the 16KLVFFA21 segment of Aβ42, forms an extended β-folded structure, and inhibits the formation of Aβ42 oligomers. mcK6A1 can be used in research of Alzheimer's disease and other amyloid-related diseases .
    mcK6A1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: